RxDoctor Payments Data

Ellen-Marie Kenny

Adult Health · New York, NYNPI 1740423680

Payments from drug & device makers

$4,831in general payments, 2019–2025

Across 151 payments — averaging $31.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$2K
  • AstraZeneca$508
  • Novo Nordisk$439
  • Novartis$322
  • E.r. Squibb & Sons, L.L.C.$273
  • Alnylam Pharmaceuticals Inc.$205
  • plus $1K from 15 others

What the payments were for

  • Food & beverage$4,69697%
  • Education$1353%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,831 in reported general payments places this provider in the 90th percentile of 3,828 adult health providers in New York.

See all adult health providers in New York

Medicare billing

Part B allowed, 2024
$6,586
Medicare patients
38
Services billed
92

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis30$1,153,056
UptraviSelexipag11$228,599
EntrestoSacubitril/Valsartan151$171,397
Ambrisentan17$94,799
EliquisApixaban44$51,241
JardianceEmpagliflozin25$34,649
FarxigaDapagliflozin Propanediol28$33,830
LokelmaSodium Zirconium Cyclosilicate14$12,125
Sildenafil Citrate11$3,181
Metoprolol Succinate90$1,450
Torsemide27$816
Amiodarone Hcl25$579
Spironolactone58$440
Digoxin16$310
Carvedilol40$294

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$37$1,204,29774 claims
Actelion Pharmaceuticals US, Inc.Uptravi$99$228,59911 claims
NovartisEntresto$322$171,397151 claims
AstraZenecaFarxiga, Lokelma$508$45,95542 claims
Boehringer IngelheimJardiance$119$34,64925 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,828 adult health providers in New York.

Other adult health in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →